In late 2019, Congress enacted the “CREATES Act”, which established a private right of action in which generic or biosimilar manufacturers may sue an innovator for an injunction and monetary award for not selling samples of an innovator product needed for purposes of developing a generic or biosimilar version. This program will explore the fundamentals of this Act in detail, recent litigation and provide recommendations for innovators to follow when a CREATES request is made.

Speakers

CLE accreditation pending.